Nura Bio
Revolutionizing treatment of neurological diseases with neuroprotective medicines
South San Francisco, United States · Founded 2018 · $143.8M raised
- Headquarters
- South San Francisco, California
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- nurabio.com
- Total Funding
- $143.8M
- Last Round
- $1.9M Pre-SeedJun 2026
- Rounds
- 3
About
Nura Bio is a clinical-stage biopharmaceutical company founded in 2018 by The Column Group and scientific founders from the Vollum Institute at Oregon Health & Science University and UT Southwestern Medical Center. The company develops neuroprotective therapies targeting fundamental pathways of axon degeneration and neuroimmune regulation, with a lead program of oral, brain-penetrant SARM1 inhibitors for ALS and other neurodegenerative diseases. Nura Bio has initiated Phase I clinical trials for its lead compound NB-4746 and completed a $73.8M Series B financing in 2026 to advance its pipeline.
Summary
Nura Bio is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $143.8M in total across 3 rounds, most recently a $1.9M Pre-Seed round in Jun 2026. Investors include The Column Group.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jun 2026
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...